Growth Opportunities in Global Protein and Peptide Therapeutics, Forecast to 2030

The protein and peptide therapeutics industry is undergoing a profound transformation, driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and GLP-1 treatments. These advances are intensifying competition, while the patent expiries of blockbuster antibodies are accelerating the entry of biosimilars and prompting lifestyle management strategies by incumbents. New monoclonal antibodies (mAbs) define drug development trends, targeting autoimmune, infectious, and cardiovascular disorders; fusion proteins with extended half-lives; innovations in enzyme replacement therapies; and cytokine engineering. Extended-release and patient-friendly formulations are improving cost efficiency, adherence, and access, while platform-based peptide methods emphasize multifunctional medicines with higher receptor selectivity and durability. Protein and peptide therapies are becoming central to precision-targeted, physiologically potent treatment options as the global disease burden rises—particularly in oncology, metabolic disorders, and autoimmune conditions. Among the fastest-growing classes are GLP-1s and multi-agonist peptides, propelled by the global obesity epidemic. Market dynamics—including steep price cuts, biosimilar expansion, and shifting treatment preferences toward GLP-1 receptor agonists—are driving a sales decline in traditional insulin products such as NovoRapid (NovoLog), Humalog, Lantus, Basaglar, and Tresiba beyond 2024. These drugs now treat not only diabetes but also obesity, sleep apnea, and cardiovascular risk. This research service covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & North Africa (MENA), providing a 6-year global revenue forecast (2025–2030) for the protein and peptide therapeutics market across segments including mAbs, fusion proteins, GLP-1 analogs, peptide hormones, coagulation factors, cytokines, interleukins, and therapeutic enzymes. It offers detailed insights into regional market trends, technological advancements, and clinical pathways, with emphasis on blockbuster drugs, biosimilars, and emerging modalities across oncology, endocrinology, infectious diseases, and immunology. Strategic insights highlight market access, growth opportunities, collaboration models, and innovation hotspots such as oral peptide delivery, targeted protein degradation, and multifunctional biologics. Show more